ReviewCannabis and cannabinoid research2020
Cannabinoids in Dermatology: Hope or Hype?
Review in Cannabis and cannabinoid research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- Harnessing machine learning and multivariate analysis to explore global trends in Cannabis sativa research.Journal of cannabis research · 2026Article
- The Potential of Cannabidiol for Treating Canine Atopic Dermatitis.Veterinary sciences · 2025Review
- The Perspective of Cannabidiol in Psoriasis Therapy.Psoriasis (Auckland, N.Z.) · 2024Review
- The Skin and Natural Cannabinoids-Topical and Transdermal Applications.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Practices and perspectives on medical cannabis and cannabinoids: A survey of the National Psoriasis Foundation Medical Advisory Board.JAAD international · 2022Article
- Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.International journal of molecular sciences · 2021Review
- Safety and Sourcing of Topical Cannabinoids: Many Questions, Few Answers.The Journal of clinical and aesthetic dermatology · 2021Review
- Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabinoids (CBDs) represent a diverse class of chemicals that may be beneficial in the treatment of various skin diseases due to antipruritic, anti-inflammatory, and antinociceptive properties. Although the legal history of these compounds has previously restricted their use and study, it seems likely that CBDs will gain popularity as they become increasingly available. We examined the mechanisms in which CBDs may have potential in the field of dermatology and reviewed the existing literature. We suggest that dermatologists review the existing evidence for CBD use and be ready to discuss it with their patients. The current literature indicates that CBDs may be beneficial in skin disease, particularly in the treatment of acne, chronic pruritus, and atopic dermatitis. Although there is preliminary evidence to suggest that CBDs are beneficial in these conditions, existing studies tend to be small and lacking rigorous design. There is a clear need for high-quality randomized controlled trials to fully evaluate the efficacy and safety of these compounds before their use can be promoted in the treatment of dermatological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.